Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Slightly Bearish -20

CRL (CRL) Form 144: 75,000-share resale via UBS Financial Services - Stock Titan

AI-generated analysis

📄 CRL filed a Form 144 notifying the SEC of a proposed resale of 75,000 shares of Common Stock.

💰 The aggregate offering price for the proposed sale is listed at $16,875,000.00.

🏦 UBS Financial Services, Inc. is identified as the broker handling the transaction.

📅 As of June 29, 2026, CRL reports 48,167,730 shares outstanding.

🎁 The sold shares originate from various RSU and PSU grants issued between 2020 and 2025.

📊 Specific grant dates include February 7, 2020; January 31, 2025; and November 14, 2023.

⚖️ The filing confirms the affiliate represents no knowledge of material adverse information regarding the issuer.

🕒 Final execution timing depends on market sales and compliance with resale conditions.

📍 The broker's address is listed as Eleven Madison Avenue, New York.

Risk Factors
  • 💸 A proposed sale of 75,000 shares valued at $16.875 million increases immediate share supply, which could exert downward pressure on the stock price upon execution.
  • 📉 The resale of restricted securities by an affiliate may signal a lack of confidence in near-term valuation or liquidity needs for insiders.
Full Analysis
CRL has filed a Form 144 with the SEC notifying of a proposed resale of 75,000 shares of its Common Stock via broker UBS Financial Services. The filing lists an aggregate offering price of $16,875,000.00 and reports 48,167,730 shares outstanding as of June 29, 2026. This statutory notice is required when an affiliate plans to sell restricted or control securities to ensure market transparency regarding potential supply increases. The shares being sold originate from multiple Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) grants issued by the company between 2020 and 2025. Specific grant dates include February 7, 2020; January 31, 2025; November 14, 2023; and May 29, 2024, among others. The filing details the nature of acquisition as RSU/PSU awards from the issuer, documenting the vesting history that led to these securities becoming eligible for resale. This disclosure indicates an affiliate intends to liquidate a portion of their holdings, potentially impacting short-term share supply and price dynamics depending on execution timing. The broker handling the transaction is UBS Financial Services, Inc., located in New York. The filing includes standard representations regarding material non-public information and adherence to Rule 10b5-1 trading plans if applicable. Financial analysts and investors should monitor the actual execution of this sale, as the aggregate value of $16.875 million represents a significant transaction relative to typical daily volume for many small-cap stocks. The timing of the sale will depend on market conditions and compliance with resale restrictions, which could influence CRL's stock price in the near term.